Physician

Karen Chee, M.D.

According to 2025 Medicare claims, Karen Chee, M.D. (NPI: 1487637310) practices medical oncology in the San Francisco-San Mateo-Redwood City, CA market, with the plurality of this provider's patient population coming from San Mateo, CA. This provider's primary affiliated billing organization is UCSF MEDICAL GROUP BUSINESS SERVICES (NPI: 1477624104; TIN: 943281660) and primary practice location at 94010-4145.

Chee's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 455 traditional Medicare patients, billed 159,065 HCPCS/CPT codes, and received $2,804,787 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 806 prescription claims across 144 beneficiaries totaling $2,865,791 in drug costs, led by Brukinsa (Zanubrutinib). DME data shows 43 claims. Open Payments data shows 5 records totaling $478. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $806,699 to $2,804,787. Similarly, Part D prescription costs have risen steadily, from $917,567 to $2,865,791. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $7,091 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	437	64,469	$806,699
2016	411	53,592	$698,533
2017	373	52,801	$766,818
2018	413	72,221	$1,007,409
2019	464	80,122	$1,036,582
2020	357	79,090	$1,303,526
2021	375	102,059	$1,741,104
2022	426	121,506	$2,579,621
2023	402	141,965	$2,339,621
2024	455	159,065	$2,804,787

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	116	634	$917,567
2016	120	680	$1,449,760
2017	113	871	$1,812,750
2018	114	713	$2,032,035
2019	127	679	$2,282,429
2020	144	837	$1,885,165
2021	142	713	$1,891,281
2022	140	766	$2,381,843
2023	150	741	$2,083,893
2024	144	806	$2,865,791

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	29	149	$78,781
2016	N/R	58	$31,103
2017	N/R	23	$7,407
2018	N/R	132	$14,875
2019	N/R	217	$12,400
2020	N/R	40	$4,348
2021	N/R	13	$1,943
2022	N/R	75	$2,877
2023	N/R	12	$6,159
2024	N/R	43	$1,361

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	100	164	$169
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	292	760	$114
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	105	148	$76
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	330	814	$15
J7030	Infusion, normal saline solution , 1000 cc	63	778	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	58	1,740	$795,629
Jakafi	Ruxolitinib Phosphate	38	1,290	$518,984
Imbruvica	Ibrutinib	21	588	$378,274
Lorbrena	Lorlatinib	12	360	$229,144
Ibrance	Palbociclib	11	308	$172,984

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	16	$903
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	13	$245
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	14	$213

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	5	$478	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Karen Chee, M.D.?

Tedicare shows public-source Medicare data for Karen Chee, M.D. (NPI 1487637310), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Karen Chee, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Karen Chee, M.D.?

Karen Chee, M.D. is linked to UCSF MEDICAL GROUP BUSINESS SERVICES (billing NPI 1477624104) in the available physician profile data.

Does Karen Chee, M.D. have Open Payments data?

Karen Chee, M.D. has 5 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.